Jiangsu Hengrui Pharmaceuticals(600276.SH): Injection SHR-9803 obtains drug clinical trial approval letter.
Hengrui Medicine (600276.SH) announced that the company recently received the Approval Notice for the Clinical Trial of Injection SHR-9803 issued by the State Drug Administration, and will soon start the clinical trial.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has recently received approval from the National Medical Products Administration for the clinical trial of injection SHR-9803, and will soon begin the trial.
After review, the clinical trial application for injection SHR-9803 submitted on December 15, 2025 meets the relevant requirements for drug registration. The company has been authorized to conduct clinical trials in advanced malignant solid tumor patients with a combination of Atezolizumab, Bevacizumab, and chemotherapy.
Related Articles
PUXING ENERGY (00090) issued a profit warning, expecting the shareholders' attributable net profit for the year 2025 to be approximately 33 million to 39 million yuan, a decrease of about 34.89% to 44.91% compared to the previous year.
XGD INC. (300130.SZ) plans to layout a new generation of intelligent hardware and launch a new brand Xalgo.
GOLDEN THROAT (06896) issues profit warning, expecting a 20%-25% year-on-year decline in operating income and profit for the fiscal year 2025.
PUXING ENERGY (00090) issued a profit warning, expecting the shareholders' attributable net profit for the year 2025 to be approximately 33 million to 39 million yuan, a decrease of about 34.89% to 44.91% compared to the previous year.
XGD INC. (300130.SZ) plans to layout a new generation of intelligent hardware and launch a new brand Xalgo.
GOLDEN THROAT (06896) issues profit warning, expecting a 20%-25% year-on-year decline in operating income and profit for the fiscal year 2025.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
